Shattuck Labs Inc (NAS:STTK)
$ 7.915 0.075 (0.96%) Market Cap: 376.37 Mil Enterprise Value: 265.75 Mil PE Ratio: 0 PB Ratio: 2.92 GF Score: 62/100

Shattuck Labs Inc at Oppenheimer Healthcare Conference (Virtual) Transcript

Mar 13, 2023 / 06:00PM GMT
Release Date Price: $2.76 (+4.15%)
Alex Xu
Oppenheimer & Co. Inc. - Analyst

Hi, my name is Alex. I work with Mark Breidenbach at Oppenheimer. Here joining me today is Taylor Schreiber. He's the CEO of Shattuck Labs.

Just a reminder for everyone, Shattuck is a clinical-stage company. They work on therapeutics that have both like agonists and inhibitor properties. Currently, their lead candidate SL-172154 is being studied in multiple indications of platinum-resistant ovarian, as well as MDS and AML. I would just give Dr. Schreiber here a chance to introduce himself.

Taylor Schreiber
Shattuck Labs, Inc. - CEO & Co-Founder

Great. Thank you, Alex, and thank you to Oppenheimer for the invitation to present at this year's healthcare conference. As Alex said, I'm Taylor Schreiber, I'm the scientific founder and CEO of Shattuck Labs.

And what I'll be telling you about today is candidates from two different technology platforms that were developed within Shattuck, by Shattuck sciences. The first, which is where our lead clinical candidate was derived, is called the agonist

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot